An appraisal of antiretroviral drugs in hemodialysis

Kidney Int. 2001 Sep;60(3):821-30. doi: 10.1046/j.1523-1755.2001.060003821.x.


Background: Acquired immunodeficiency syndrome (AIDS)-related kidney disorders concern 30% of those patients and can lead to end-stage renal disease (ESRD; 6 to 10%). Therefore, the administration of antiretroviral drugs in human immunodeficiency virus (HIV) patients with nephropathy is not uncommon.

Methods: The influence of ESRD on the different phases of the pharmacokinetic profile of drugs in general is examined in light of bioavailability, distribution, protein binding, metabolism, and elimination. Then, the pharmacokinetics of antiretroviral drugs in hemodialysis are detailed.

Results: From these data, dosing recommendations are given for nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs, and protease inhibitors (PIs).

Conclusion: Dosage adjustments are often necessary for patients with renal insufficiency. These adaptations have to be carefully performed to optimize drug exposure and reduce the risk of side effects.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Acquired Immunodeficiency Syndrome / drug therapy
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / pharmacokinetics*
  • Area Under Curve
  • Drug Administration Schedule
  • Guidelines as Topic
  • Humans
  • Molecular Structure
  • Protease Inhibitors / pharmacokinetics
  • Renal Dialysis*
  • Renal Insufficiency / complications*
  • Renal Insufficiency / metabolism
  • Renal Insufficiency / therapy
  • Reverse Transcriptase Inhibitors / pharmacokinetics


  • Anti-HIV Agents
  • Protease Inhibitors
  • Reverse Transcriptase Inhibitors